Literature DB >> 1918996

Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation.

C V Harding1, D S Collins, O Kanagawa, E R Unanue.   

Abstract

Liposome-encapsulated protein Ag were used to dissect the roles of various subcellular compartments in Ag processing for class I and class II MHC-restricted presentation. Macrophages exhibited efficient processing of Ag encapsulated in acid-resistant dioleoylphosphatidylcholine/dioleoylphosphatidylserine liposomes, which sequester their contents from potential endosomal processing events and release them only after delivery to lysosomes. Lysosomal processing was demonstrated for all four Ag studied (OVA, murine hemoglobin, bovine ribonuclease A, and hen egg lysozyme), establishing the recycling of immunogenic peptides from lysosomes after Ag processing. These acid-resistant liposomes did not engender class I processing. Ag encapsulated within acid-sensitive dioleoylphosphatidylethanolamine/palmitoylhomocysteine liposomes were also processed via the class II pathway. Of the four Ag encapsulated in liposomes, one, OVA, was tested for ability to stimulate a class I-specific response. OVA in acid-resistant liposomes did not engender a class I-specific response. In contrast, OVA encapsulated in acid-sensitive liposomes was presented by class I molecules, albeit less efficiently than it was presented by class II molecules. We interpret this to be the result of the release of a minor portion of the encapsulated Ag into the cytosol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918996

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Antigen processing and CD24 expression determine antigen presentation by splenic CD4+ and CD8+ dendritic cells.

Authors:  David Askew; Clifford V Harding
Journal:  Immunology       Date:  2007-10-19       Impact factor: 7.397

Review 2.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 3.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

4.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

Review 5.  Tumor targeting via EPR: Strategies to enhance patient responses.

Authors:  Susanne K Golombek; Jan-Niklas May; Benjamin Theek; Lia Appold; Natascha Drude; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2018-07-19       Impact factor: 15.470

Review 6.  Physiological functions of endosomal proteolysis.

Authors:  T Berg; T Gjøen; O Bakke
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

7.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies.

Authors:  J M Brewer; J Richmond; J Alexander
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Compartmentalization of defined epitopes expressed in Escherichia coli has only a minor influence on efficiency of phagocytic processing for presentation by class I and class II major histocompatibility complex molecules to T cells.

Authors:  M J Wick; J D Pfeifer; K A Findlay; C V Harding; S J Normark
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway.

Authors:  C Walker; M Selby; A Erickson; D Cataldo; J P Valensi; G V Van Nest
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.